Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy

International Journal of Molecular Sciences

Volumn 14, Issue 6, 2013, Pages 12297-12312

  Kunze, Doreen ^a   Erdmann, Kati ^a   Froehner, Michael ^a   Wirth, Manfred P ^a   Fuessel, Susanne ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Apoptosis; Bcl xl; Bcl2l1; Birc5; Bladder cancer; Chemotherapy; Combination therapy; Rna interference; Sirna; Survivin

Indexed keywords

CISPLATIN; MESSENGER RNA; MITOMYCIN; PROTEIN BCL XL; SMALL INTERFERING RNA; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL X;

APOPTOSIS; ARTICLE; BCL XL GENE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; SURVIVIN GENE; TUMOR GENE; CELL COUNT; CELL DEATH; CELL SURVIVAL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; POLYPLOIDY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL COUNT; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; POLYPLOIDY; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 84879011629     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140612297     Document Type: Article

References (37)

1. Ferlay, J.; Parkin, D.M.; Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46, 765-781.
2. Sylvester, R.J.; Brausi, M.A.; Kirkels, W.J.; Hoeltl, W.; Calais Da Silva, F.; Powell, P.H.; Prescott, S.; Kirkali, Z.; van de Beek, C.; Gorlia, T.; et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur. Urol. 2010, 57, 766-773.
3. Witjes, J.A.; Compérat, E.; Cowan, N.C.; de Santis, M.; Gakis, G.; Lebret, T.; Ribal, M.J.; Sherif, A. Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Uroweb 2013. Available online: http://www.uroweb.org/gls/pdf/07_Bladder%20Cancer_LRV2.pdf (accessed on 17 April 2013).
4. Babjuk, M.; Burger, M.; Zigeuner, R.; Shariat, S.F.; van Rhijn, B.; Compérat, E.; Sylvester, R.J.; Kaasinen, E.; Böhle, A.; Palou, J.; et al. Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). Uroweb 2013. Available online: http://www.uroweb.org/gls/pdf/ 05_TaT1_Bladder_Cancer_LR.pdf (accessed on 17 April 2013).
5. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646-674.
6. Kunze, D.; Kraemer, K.; Erdmann, K.; Froehner, M.; Wirth, M.P.; Fuessel, S. Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int. J. Oncol. 2012, 41, 1271-1277.
7. Ning, S.; Fuessel, S.; Kotzsch, M.; Kraemer, K.; Kappler, M.; Schmidt, U.; Taubert, H.; Wirth, M.P.; Meye, A. SiRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int. J. Oncol. 2004, 25, 1065-1071.
8. Kunze, D.; Erdmann, K.; Froehner, M.; Wirth, M.P.; Fuessel, S. SiRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells. Anticancer Res. 2012, 32, 4313-4318.
9. Ryan, B.M.; O'Donovan, N.; Duffy, M.J. Survivin: A new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35, 553-562.
10. Shariat, S.F.; Ashfaq, R.; Karakiewicz, P.I.; Saeedi, O.; Sagalowsky, A.I.; Lotan, Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007, 109, 1106-1113.
11. Dohi, T.; Okada, K.; Xia, F.; Wilford, C.E.; Samuel, T.; Welsh, K.; Marusawa, H.; Zou, H.; Armstrong, R.; Matsuzawa, S.; et al. An IAP-IAP complex inhibits apoptosis. J. Biol. Chem. 2004, 279, 34087-34090.
12. Brunelle, J.K.; Letai, A. Control of mitochondrial apoptosis by the Bcl-2 family. J. Cell Sci. 2009, 122, 437-441.
13. Korkolopoulou, P.; Lazaris, A.; Konstantinidou, A.E.; Kavantzas, N.; Patsouris, E.; Christodoulou, P.; Thomas-Tsagli, E.; Davaris, P. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur. Urol. 2002, 41, 274-283.
14. Hunter, A.M.; LaCasse, E.C.; Korneluk, R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007, 12, 1543-1568.
15. Jeyaprakash, A.A.; Klein, U.R.; Lindner, D.; Ebert, J.; Nigg, E.A.; Conti, E. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 2007, 131, 271-285.
16. Fuessel, S.; Herrmann, J.; Ning, S.; Kotzsch, M.; Kraemer, K.; Schmidt, U.; Hakenberg, O.W.; Wirth, M.P.; Meye, A. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett. 2006, 232, 243-254.
17. Kappler, M.; Bache, M.; Bartel, F.; Kotzsch, M.; Panian, M.; Wurl, P.; Blumke, K.; Schmidt, H.; Meye, A.; Taubert, H. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther. 2004, 11, 186-193.
18. Saito, T.; Hama, S.; Izumi, H.; Yamasaki, F.; Kajiwara, Y.; Matsuura, S.; Morishima, K.; Hidaka, T.; Shrestha, P.; Sugiyama, K.; et al. Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells. Br. J. Cancer 2008, 98, 345-355.
19. Ramachandran, P.V.; Ignacimuthu, S. RNA interference as a plausible anticancer therapeutic tool. Asian Pac. J. Cancer Prev. 2012, 13, 2445-2452.
20. Fuessel, S.; Kunze, D.; Kraemer, K.; Schwenzer, B.; Meye, A.; Wirth, M.P. Chemosensitization of Human Bladder Cancer Cells by Pre-Treatment with Nucleic Acid Inhibitors: Antiproliferative Effects and Specificity. In Chemo-Immunosensitization of Resistant Tumor Cells to Apoptosis; Bonavida, B., Ed.; Transworld Research Network: Kerala, Indien, 2006; pp. 13-36.
21. Lonning, P.E.; Knappskog, S. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene 2013, doi:10.1038/onc.2013.48.
22. Fulda, S. Inhibitor of Apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers. Cancer Treat. Rev. 2012, 38, 760-766.
23. Shimura, T. Acquired radioresistance of cancer and the AKT/GSK3beta/cyclin D1 overexpression cycle. J. Radiat. Res. 2011, 52, 539-544.
24. Hao, J.H.; Gu, Q.L.; Liu, B.Y.; Li, J.F.; Chen, X.H.; Ji, Y.B.; Zhu, Z.G.; Lin, Y.Z. Inhibition of the proliferation of human gastric cancer cells SGC-7901 in vitro and in vivo using Bcl-2 siRNA. Chin. Med. J. 2007, 120, 2105-2111.
25. Liu, Y.; Wu, X.; Sun, Y.; Chen, F. Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer. J. Int. Med. Res. 2011, 39, 1682-1692.
26. Jeong, J.Y.; Kim, K.S.; Moon, J.S.; Song, J.A.; Choi, S.H.; Kim, K.I.; Kim, T.H.; An, H.J. Targeted inhibition of phosphatidyl inositol-3-kinase p110beta, but not p110alpha, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis 2013, 18, 509-520.
27. Han, Z.; Chatterjee, D.; Early, J.; Pantazis, P.; Hendrickson, E.A.; Wyche, J.H. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Cancer Res. 1996, 56, 1621-1628.
28. Wang, Q.; Shu, R.; He, H.; Wang, L.; Ma, Y.; Zhu, H.; Wang, Z.; Wang, S.; Shen, G.; Lei, P. Co-silencing of Birc5 (survivin) and Hspa5 (Grp78) induces apoptosis in hepatoma cells more efficiently than single gene interference. Int. J. Oncol. 2012, 41, 652-660.
29. Yang, D.; Song, X.; Zhang, J.; Ye, L.; Wang, S.; Che, X.; Wang, J.; Zhang, Z.; Wang, L.; Shi, W. Therapeutic potential of siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP, and Survivin) on human bladder cancer T24 cells. Acta Biochim. Biophys. Sin. 2010, 42, 137-144.
30. Kim, D.W.; Seo, S.W.; Cho, S.K.; Chang, S.S.; Lee, H.W.; Lee, S.E.; Block, J.A.; Hei, T.K.; Lee, F.Y. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells. J. Orthop. Res. 2007, 25, 820-828.
31. Di Cresce, C.; Figueredo, R.; Ferguson, P.J.; Vincent, M.D.; Koropatnick, J. Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed. J. Pharmacol. Exp. Ther. 2011, 338, 952-963.
32. Gill, C.; Dowling, C.; O'Neill, A.J.; Watson, R.W. Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol. Cancer 2009, 8, 39.
33. Gavrilov, K.; Saltzman, W.M. Therapeutic siRNA: principles, challenges, and strategies. Yale J. Biol. Med. 2012, 85, 187-200.
34. Whitehead, K.A.; Langer, R.; Anderson, D.G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8, 129-138.
35. Davis, M.E.; Zuckerman, J.E.; Choi, C.H.; Seligson, D.; Tolcher, A.; Alabi, C.A.; Yen, Y.; Heidel, J.D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067-1070.
36. Seth, S.; Matsui, Y.; Fosnaugh, K.; Liu, Y.; Vaish, N.; Adami, R.; Harvie, P.; Johns, R.; Severson, G.; Brown, T.; et al. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol. Ther. 2011, 19, 928-935.
37. WinMDI2.8 software. Available online: http://facs.scripps.edu/software.html (accessed on 17 April 2013).